Interleukin‐23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A (+) Osteoclast Precursors
Arthritis & Rheumatology · 2023-08 · 75 (8) · 1477-1489
DOI: 10.1002/art.42478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 06.06.2023. Verfasst von Hiroki Furuya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Bone Resorption, Arthritis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
To investigate the role of interleukin‐23 (IL‐23) in pathologic bone remodeling in inflammatory arthritis.
Methods
In this study we investigated the role of IL‐23 in osteoclast differentiation and activation using in vivo gene transfer techniques in wild‐type and myeloid DNAX‐activation protein 12–associating lectin‐1 (MDL‐1)–deficient mice, and by performing in vitro and in vivo osteoclastogenesis assays using spectral flow cytometry, micro–computed tomography analysis, Western blotting, and immunoprecipitation.
Results
Herein, we show that IL‐23 induces the expansion of a myeloid osteoclast precursor population and supports osteoclastogenesis and bone resorption in inflammatory arthritis. Genetic ablation of C‐type lectin domain family member 5A, also known as MDL‐1, prevents the induction of osteoclast precursors by IL‐23 that is associated with bone destruction, as commonly observed in inflammatory arthritis. Moreover, osteoclasts derived from the bone marrow of MDL‐1–deficient mice showed impaired osteoclastogenesis, and MDL‐1 −/− mice had increased bone mineral density.
Conclusion
Our data show that IL‐23 signaling regulates the availability of osteoclast precursors in inflammatory arthritis that could be effectively targeted for the treatment of inflammatory bone loss in inflammatory arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis.
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.
- Department of Dermatology, University of California, Davis, Sacramento, California.
- Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, and Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis.
ORCID-Profile: Hiroki Furuya, Cuong Thach Nguyen, Iannis E Adamopoulos
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Furuya, H., Nguyen, C. T., Gu, R., Hsieh, S. L., Maverakis, E., & Adamopoulos, I. E. (2023). Interleukin‐23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A (+) Osteoclast Precursors. Arthritis & Rheumatology, 75(8), 1477-1489. https://doi.org/10.1002/art.42478
Vancouver
Furuya H, Nguyen CT, Gu R, Hsieh SL, Maverakis E, Adamopoulos IE. Interleukin‐23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A (+) Osteoclast Precursors. Arthritis & Rheumatology. 2023;75(8):1477-1489. doi:10.1002/art.42478
BibTeX
@article{Furuya2023,
author = {Furuya, Hiroki and Nguyen, Cuong Thach and Gu, Ran and Hsieh, Shie-Liang and Maverakis, Emanual and Adamopoulos, Iannis E},
title = {Interleukin‐23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A (+) Osteoclast Precursors},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {8},
pages = {1477--1489},
doi = {10.1002/art.42478}
}
EUVIMED